(Q44011194)

28 November 2017

The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome (English)

1 reference

28 November 2017

1 reference

Kasiske BL

1

1 reference

28 November 2017

Velosa JA

2

1 reference

28 November 2017

Halstenson CE

3

1 reference

28 November 2017

La Belle P

4

1 reference

28 November 2017

Langendörfer A

5

1 reference

28 November 2017

Keane WF

6

1 reference

28 November 2017

1 January 1990

1 reference

American Journal of Kidney Diseases

28 November 2017

1 reference

28 November 2017

15

1 reference

28 November 2017

1

1 reference

28 November 2017

8-15

1 reference

Ischaemic heart-disease as a complication of nephrotic syndrome

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

Does the nephrotic syndrome increase the risk of cardiovascular disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

The Nephrotic Syndrome and Ischaemic Heart Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

Relation of hyperlipidemia in serum and loss of high density lipoproteins in urine in the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

Serum and urinary high density lipoproteins in glomerular disease with proteinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

Lipoprotein distribution and composition in the human nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

EFFECTS OF SIMVASTATIN AND CHOLESTYRAMINE ON LIPOPROTEIN PROFILE IN HYPERLIPIDAEMIA OF NEPHROTIC SYNDROME

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

Suprofen-induced uricosuria. A potential mechanism for acute nephropathy and flank pain

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

Renal extraction of para-aminohippurate and creatinine measured by continuous in vivo sampling of arterial and renal-vein blood

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

Effect of probucol on hyperlipidemia in patients with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

Hypertriglyceridemia: a contraindication to the use of bile acid binding resins

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980586-5

7 January 2021

10.1016/S0272-6386(12)80586-5

Identifiers

DOI

1 reference

28 November 2017

1 reference